AbbVie nears $11 billion deal to acquire Apogee Therapeutics
AbbVie is closing in on a nearly $11 billion deal to acquire inflammatory disease drug developer Apogee Therapeutics, according to a Financial Times report, sending Apogee shares soaring. Meanwhile, Regenxbio received FDA confirmation that no additional studies are needed for its gene therapy Navsunli, targeting Mucopolysaccharidosis II, clearing the path for potential accelerated approval. SpaceX shares continued to slide following their record IPO.
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!